Abstract:Berberine, a well-known alkaloid, has been proved to possess various pharmacological activities. Previous studies demonstrated that berberine could be extensively metabolized and the metabolites also contributed to its therapeutic effects. However, as for berberine’s metabolites, especially phase II metabolites, pharmacokinetics and excretion studies were rarely reported. The objective of this study was to thoroughly investigate the pharmacokinetic and excretion profiles of berberine and its nine metabolites, namely, berberrubine (M1), demethyleneberberine (M2), jatrorrhizine (M3), jatrorrhizine-3- O-β -D-glucuronide (M4), jatrorrhizine-3- O -sulfate (M5), thalfendine-10- O-β -D-glucuronide (M6), berberrubine-9- O-β -D-glucuronide (M7), demethyleneberberine-2- O -sulfate (M8) and demethyleneberberine-2- O-β -D-glucuronide (M9) in rats. An accurate and reliable LC-MS/MS method was developed and validated for the determination of berberine and its nine metabolites in rat biosamples. Pharmacokinetic profiles of berberine and its nine metabolites were obtained after a single intravenous administration (4.0 mg/kg) and oral administration (48.2, 120 or 240 mg/kg) of berberine in rats. For excretion study, rats were intragastrically administered a single dose of 48.2 mg/kg berberine. Our results showed that berberine could be metabolized rapidly and all the nine metabolites could be detected in vivo . The absolute bioavailability of berberine was 0.37 ± 0.11%. As for the AUC 0–48 h values, phase II metabolites were much higher than those of phase I metabolites, suggesting that phase II metabolites were the major metabolites exist in blood circulation. 18.6% of the berberine was excreted in feces as berberrubine (M1). The total recovery of berberine and its nine metabolites from urine, bile and feces was 41.2%. This is the first systematic study about the pharmacokinetics and excretion of berberine and its nine metabolites, which will be beneficial for both better understanding the clinical effects and further development of berberine.

Characterization Of The Transportation Of Berberine In Coptidis Rhizoma Extract Through Rat Primary Cultured Cortical Neurons

The Uptake and Transport Behavior of Berberine in Coptidis Rhizoma Extract Through Rat Primary Cultured Cortical Neurons

Influence of coptis Chinensis on pharmacokinetics of flavonoids after oral administration of radix Scutellariae in rats.

Pharmacokinetics of Berberine in Rat Intestinal and Bile Following Intravenous Administration of Coptidis Rhizoma Extract

CYP450 1A2 and multiple UGT1A isoforms are responsible for jatrorrhizine metabolism in human liver microsomes.

Naturally occurring proteinaceous nanoparticles in Coptidis Rhizoma extract act as concentration-dependent carriers that facilitate berberine absorption

Pharmacokinetics of Berberine in Rat Cerebral Nuclei Following Intravenous Administration of Coptidis Rhizoma Extract

Pharmacokinetics of berberine in rat thalamus after intravenous administration of Coptidis rhizoma extract.

Kinetic difference of berberine between hippocampus and plasma in rat after intravenous administration of Coptidis rhizoma extract.

Intestinal absorption mechanisms of berberine, palmatine, jateorhizine, and coptisine: involvement of P-glycoprotein

Inhibition of organic cation transporter 2 and 3 may be involved in the mechanism of the antidepressant-like action of berberine.

Absorption of Coptisine Chloride and Berberrubine Across Human Intestinal Epithelial by Using Human Caco-2 Cell Monolayers

Natural Nano-Drug Delivery System in Coptidis Rhizoma Extract with Modified Berberine Hydrochloride Pharmacokinetics

The uptake behaviors of kaempferol and quercetin through rat primary cultured cortical neurons.

Pharmacokinetics and Excretion of Berberine and Its Nine Metabolites in Rats

Extensive intestinal first-pass elimination and predominant hepatic distribution of berberine explain its low plasma levels in rats.

[Study on the tissue distribution of berberine from Rhizoma Coptidis and compatibility with Rhizoma Coptidis and Cortex Cinnamomi in rats].

Interaction of Six Protoberberine Alkaloids with Human Organic Cation Transporters 1, 2 and 3.

Transportation of Berberine into HepG2, HeLa and SY5Y Cells: a Correlation to Its Anti-Cancer Effect.

Oxidative demethylenation and subsequent glucuronidation are the major metabolic pathways of berberine in rats.

Nanoemulsion-based delivery system for enhanced oral bioavailability and caco-2 cell monolayers permeability of berberine hydrochloride